Brief: HBC Publishes Clinical Trial, Calls It Paradigm-Changing
14/04/2026 10:10
April 14 (Reuters) - Hofseth Biocare ASA HBC.OL: ANNOUNCES PUBLICATION OF HEAD-TO-HEAD CLINICAL TRIAL RESULTS FOR OMEGO OMEGO INCREASES OMEGA 3 INDEX BY OVER 70% AFTER 14 WEEKS VERSUS COMPARATOR OMEGO MORE EFFECTIVE AT REDUCING INFLAMMATORY MARKERS HSCRP, TNFA, AND IL-6 CLINICAL STUDY CHALLENGES ASSUMPTION THAT HIGHER-DOSE FISH OILS DELIVER GREATER BENEFITS Source text: ID:nGNE198xZK Further company coverage: HBC.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hofseth Biocare ASA
See all newsBrief: HBC Publishes Clinical Trial, Calls It Paradigm-Changing
Brief: Hofseth Biocare Says Demand Outlook For 2026 Is Improving Rapidly
Norway's Hofseth Biocare Q4 revenue rises on Human Nutrition demand
Brief: Hofseth BioCare To Cancel Subsequent Offering
Brief: Hofseth Biocare Announces Results Of Subsequent Offering